MedTrace Logo

A Study of PRCL-02 in Healthy Volunteers and Plaque Psoriasis

NCT03062618 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-03-07

No results posted yet for this study

Summary

This study consists of three parts: single oral dose escalation in healthy volunteers (Part A), and multiple oral dose escalations in healthy volunteers (Part B) and in participants with chronic plaque psoriasis (Part C)

Conditions

Interventions

DRUG

PRCL-02

Oral tablet(s) administered with water

DRUG

Placebo Oral Tablet

Administered with water

Sponsors & Collaborators

  • PRCL Research Inc.

    lead OTHER

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-20
Primary Completion
2018-02-08
Completion
2018-02-08
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03062618 on ClinicalTrials.gov